Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8882067 | 1.00 | ALDH1A1 (0.59) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL6926208 | 1.00 | ALDH1A1 (0.59) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL18337953 | 0.96 | ALDH1A1 (0.65) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL18337954 | 0.96 | ALDH1A1 (0.65) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL5702208 | 0.93 | NPC1 (0.58) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL6928231 | 0.93 | NPC1 (0.58) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL5701909 | 0.93 | NPC1 (0.58) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL28902285 | 0.88 | NPC1 (0.66) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL7981690 | 0.85 | ALDH1A1 (0.58) | ALDH1A1KMT2AMCOLN3NPC1MEN1 | |
| SCHEMBL6096659 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AMCOLN3NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| EP-1828246-A1 | MYD88 HOMODIMERIZATION INHIBITORS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067091-A1 | MYD88 HOMODIMERIZATION INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-06-29 | — | — | WO | disclosed |
| EP-1321454-A1 | PROCESS FOR THE REMOVAL OF NITROBENZENESULFONYL | Kaneka Corporation (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-6515179-B2 | Reacting nitrobenzenesulfonyl group containing compound contacting with alkali metal alkoxide | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20030009056-A1 | PROCESS FOR THE REMOVAL OF NITROBENZENESULFONYL | KANEKA CORPORATION (JP) | 2003-01-09 | — | — | US | disclosed |
| US-5677316-A | BACTERICIDES | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0677522-A1 | 8-METHOXYQUINOLONECARBOXYLIC ACID DERIVATIVE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5273998-A | Process for making an optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compound | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| US-5177216-A | DIASTEREOMERIC ESTER COMPOUND USEFUL AS AN INTERMEDIATE IN THE MAKING OF AN OPTICALLY ACTIVE 3,4-DIHYDRO-3,4-EPOXY-2H-1-BENZOPYRAN COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0456266-A1 | Method for preparing optically active 3,4-dihydro-3,4-epoxy-2H-1-benzopyran compounds, intermediates therefor and uses thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1991-11-13 | — | — | EP | disclosed |
| US-4482486-A | Analogs of vasopressin | CESKOSLOVENSKA AKADEMIE VED (CS) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | ALDH1A1 4229/4885KMT2A 3707/4885MCOLN3 3297/4885 |
| US-20030009056-A1 | PROCESS FOR THE REMOVAL OF NITROBENZENESULFONYL | NAAA, TST, AADAC | ALDH1A1 2030/4885KMT2A 82/4885MCOLN3 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.